“Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II”, J of Skin, vol. 9, no. 6, p. s707, Nov. 2025, doi: 10.25251/fpf9fe87.